Related references
Note: Only part of the references are listed.KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers
A. I. Phipps et al.
BRITISH JOURNAL OF CANCER (2013)
Targeting FLIP and Mcl-1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to TRAIL
Bodvael Pennarun et al.
JOURNAL OF PATHOLOGY (2013)
Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation-diversity, ductility, and destiny
Kenichi Suda et al.
CANCER AND METASTASIS REVIEWS (2012)
MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors
Alexa B. Turke et al.
CANCER RESEARCH (2012)
A systematic review of treatment guidelines for metastatic colorectal cancer
M. S. Edwards et al.
COLORECTAL DISEASE (2012)
Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma
Hung Huynh et al.
JOURNAL OF HEPATOLOGY (2012)
Dovitinib Induces Apoptosis and Overcomes Sorafenib Resistance in Hepatocellular Carcinoma through SHP-1-Mediated Inhibition of STAT3
Wei-Tien Tai et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer
Shikha Gaur et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2012)
KRAS, BRAF and PIK3CA Mutations and the Loss of PTEN Expression in Chinese Patients with Colorectal Cancer
Chen Mao et al.
PLOS ONE (2012)
The Prognostic Value of BRAF Mutation in Colorectal Cancer and Melanoma: A Systematic Review and Meta-Analysis
Gholamreza Safaee Ardekani et al.
PLOS ONE (2012)
Inhibitors of mTOR overcome drug resistance from topoisomerase II inhibitors in solid tumors
Shikha Gaur et al.
CANCER LETTERS (2011)
Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma
Kevin B. Kim et al.
CLINICAL CANCER RESEARCH (2011)
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers
Hiromichi Ebi et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Targeting FGFR/PDGFR/VEGFR Impairs Tumor Growth, Angiogenesis, and Metastasis by Effects on Tumor Cells, Endothelial Cells, and Pericytes in Pancreatic Cancer
Johannes Taeger et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Evidence for colorectal cancer screening
Michael Bretthauer
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2010)
Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Targeting Fibroblast Growth Factor Receptors Blocks PI3K/AKT Signaling, Induces Apoptosis, and Impairs Mammary Tumor Outgrowth and Metastasis
Julien H. Dey et al.
CANCER RESEARCH (2010)
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
Marc Peeters et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Jean-Yves Douillard et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Accumulation of driver and passenger mutations during tumor progression
Ivana Bozic et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
PI-3-K and AKT: Onto the mitochondria
Bangyan L. Stiles
ADVANCED DRUG DELIVERY REVIEWS (2009)
Noninvasive Detection of Lentiviral-Mediated Choline Kinase Targeting in a Human Breast Cancer Xenograft
Balaji Krishnamachary et al.
CANCER RESEARCH (2009)
Cancer-Specific High-Throughput Annotation of Somatic Mutations: Computational Prediction of Driver Missense Mutations
Hannah Carter et al.
CANCER RESEARCH (2009)
Design, Structure-Activity Relationships and in Vivo Characterization of 4-Amino-3-benzimidazol-2-ylhydroquinolin-2-ones: A Novel Class of Receptor Tyrosine Kinase Inhibitors
Paul A. Renhowe et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Inhibition of receptor tyrosine kinases in combination with chemotherapy for the treatment of breast cancer
S. L. Moulder et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2008)
The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells
Pablo G. Longo et al.
BLOOD (2008)
A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors
Debashis Sarker et al.
CLINICAL CANCER RESEARCH (2008)
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The genomic landscapes of human breast and colorectal cancers
Laura D. Wood et al.
SCIENCE (2007)
Activity of TK1258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome
Andrew Chase et al.
BLOOD (2007)
Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy
Rosalind H. Gunby et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2007)
Role of tyrosine kinase inhibitors in the treatment of advanced colorectal cancer
Cristina Gravalos et al.
CLINICAL COLORECTAL CANCER (2007)
A multidimensional analysis of genes mutated in breast and colorectal cancers
Jimmy Lin et al.
GENOME RESEARCH (2007)
Colorectal cancer: genetics of development and metastasis
T Takayama et al.
JOURNAL OF GASTROENTEROLOGY (2006)
Role of tyrosine kinase inhibitors in cancer therapy
A Arora et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
O Casanovas et al.
CANCER CELL (2005)
CHIR-258: A potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia
DEL de Menezes et al.
CLINICAL CANCER RESEARCH (2005)
In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models
SH Lee et al.
CLINICAL CANCER RESEARCH (2005)
Tyrosine kinase inhibitor resistance in cancer:: role of ABC multidrug transporters
C Özvegy-Laczka et al.
DRUG RESISTANCE UPDATES (2005)
Involvement of ras activation in human breast cancer cell signaling, invasion, and anoikis
LB Eckert et al.
CANCER RESEARCH (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer
C Fondevila et al.
BRITISH JOURNAL OF CANCER (2004)
Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?
GA Repasky et al.
TRENDS IN CELL BIOLOGY (2004)
Angiogenesis in health and disease
P Carmeliet
NATURE MEDICINE (2003)
The BCL2 family: Regulators of the cellular life-or-death switch
S Cory et al.
NATURE REVIEWS CANCER (2002)
Live or let die: The cell's response to p53
KH Vousden et al.
NATURE REVIEWS CANCER (2002)
The phosphatidylinositol 3-kinase-AKT pathway in human cancer
I Vivanco et al.
NATURE REVIEWS CANCER (2002)
The molecular basis and potential role of survivin in cancer diagnosis and therapy
DC Altieri
TRENDS IN MOLECULAR MEDICINE (2001)
Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death
A Suzuki et al.
ONCOGENE (2000)
Share Paper
